AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis About Howard Lake Howard Lake is a digital fundraising entrepreneur. Publisher of UK Fundraising, the world’s first web resource for professional fundraisers, since 1994. Trainer and consultant in digital fundraising. Founder of Fundraising Camp and co-founder of GoodJobs.org.uk. Researching massive growth in giving. McManus to host world’s biggest charity golf event Irish financier and philanthropist, JP McManus, is hosting the world’s most lucrative charity golf event on July 4th and 5th at Adare Manor in County Limerick. Held every five years, the last JP McManus Invitational Pro-Am raised ‚€20 million for local charities. This year the event, which will be attended once again by golfing superstars such as Tiger Woods, Stuart Appleby, Padraig Harrington and Mark O’Meara, culminates in what its organisers describe as the biggest private party ever thrown in Ireland.1,100 invitations have been issued to professional and amateur golfers, who include some of McManus’s closest friends in the financial world. Apart from a few charity teams that have raised ‚€10,000 to enter, 56 amateur teams are paying ‚€100,000 to play. Advertisement 23 total views, 1 views today AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis McManus’s philosophy is to help those who help themselves, so even the charity teams who managed to raise smaller amounts can, via a qualifier, where individuals paid just ‚€20 to enter, have a chance of playing alongside Tiger Woods.The post golf party and auction is also an important part of the fundraising with a painting of McManus and his friends celebrating an Istabraq win going for ‚€1.4 last time. Most recent estimates put McManus’s personal wealth at ‚€730 million. Howard Lake | 25 June 2005 | News Tagged with: Events Ireland Recruitment / people
Drug Lobby Plans Counter A Post-Election Ad War On Drug PricesBy SARAH KARLIN-SMITH for Politico Washington’s powerful drug lobby is gearing up to spend hundreds of millions of dollars on a post-election ad war pushing back against politicians from both parties who have savaged its members over drug prices.The massive campaign by the Pharmaceutical Research and Manufacturers of America — expected to start positive by highlighting drugs that save or prolong lives — will dwarf the $20 million that health insurers spent on the iconic “Harry and Louise” campaign credited with sinking Hillary Clinton’s health reform plan in the early 1990s.Targeting politicians is not part of the initial plan, but lobbyists say the organization is prepared to do so if members of Congress or the executive branch push agendas that are seen as detrimental to the industry.And that’s just one part of a larger effort by the K Street lobbying powerhouse to seize control of the public narrative over drug prices and to reassert its dominance in Washington after several years in which it has taken a public shellacking over prices, with even reliable political allies in Congress questioning its pricing strategies. Both Clinton and Donald Trump, for instance, are urging changes in the law that would allow the government to negotiate drug prices for Medicare beneficiaries.PhRMA wants to drive a broader discussion on health costs, emphasizing that other players must play a role in tamping down costs and offering to work with insurers and others to find solutions, senior company officials and lobbyists said.“The reality and the message and the playbook used for a number of years is over,” said Bill Pierce, senior director of the public affairs firm APCO Worldwide, which represents several drug companies, and a former HHS official under President George W. Bush.The industry can no longer defend high drug prices by pointing to the pricey research and development that goes into innovative medicines. “They have to move on,” he said.The perception among drug industry insiders is that the pharmaceutical lobby let its guard down six years ago after getting a lot of what it wanted in Obamacare — and keeping out what it didn’t. But in the last few years, it was blindsided by organized campaigns against high drug prices and growing public alarm about the cost of medicine. Public outrage has been stoked by the eye-popping costs of breakthrough drugs such as a new generation of hepatitis C cures, pharmaceutical companies’ attempts to merge with firms overseas to avoid U.S. taxes, and former pharmaceutical CEO Martin Shkreli’s decision to hike the price of a drug relied upon by AIDS patients by more than 5,000 percent.“The ground has shifted underneath the industry from where it was five years ago, certainly 10 years ago, but I even think in the last two years,” Pierce said.By DAN DIAMONDDrug companies are used to Democrats attacking prices, but Republicans are also starting to chide the industry for large hikes on old drugs and raising concerns about the financial burden that prescription drugs place on entitlement programs.Just last week, Sen. Chuck Grassley (R-Iowa) expressed concern that drug companies “might be exploiting” Medicare’s prescription drug benefit “to maximize their market share.” The program’s catastrophic coverage requires the government to pick up the tab for most patients’ drug costs after $4,850 per year — spending which has increased by 85 percent in three years.Those and other calls — including the demand by both presidential candidates that Medicare negotiate drug prices — have awakened a sleeping giant, which routinely spends more on lobbying than any other health care group and took in more than $200 million in member dues in 2014, compared to about $80 million for the American Hospital Association and about $41 million for America’s Health Insurance Plans.The group’s playbook for 2017 includes adding new members, raising dues and retooling a lobbying machine that insiders say atrophied since PhRMA achieved many of its top goals with Obamacare’s passage. Now it’s ready to shout its message not just inside the corridors of power but beyond the Beltway.PhRMA has already flexed its muscles this year, fighting back against the Obama administration’s proposal to lower payments for some high-cost drugs administered in doctor’s offices. The Hill blowback — which has come from some Democrats as well as Republicans — has demonstrated how difficult it will be for a future White House to enact drug pricing legislation, especially now that industry is getting a head start.PhRMA’s board this summer added Teva, the world’s largest generic company, to its ranks, along with Alexion Pharmaceuticals and Jazz Pharmaceuticals. It also elevated Horizon Pharma and AMAG Pharmaceuticals to full members and raised dues on all companies.“The combination of new voices and resources will also bolster our efforts to engage with all stakeholders and advocate for proactive policies that promote continued medical progress,” said PhRMA CEO Stephen Ubl.Industry insiders and lobbyists say the trade association is also looking to add more companies as members, including big-name players like Gilead — the maker of costly hepatitis C drugs that helped spur public backlash over prices — and Genentech. Representatives from the companies attended the July PhRMA board meeting, the two companies saidPhRMA’s dues are based on companies’ sales, so adding Gilead and Genentech would be a huge boost for the lobby group. Gilead took in more than $15 billion in the first half of the year, while Roche — Genentech’s parent company — had $19.5 billion in drug sales during this period.Officials would talk about the ad campaign only in broad terms, but the tone is expected to be positive, like the Washington-centric “Hope to Cures” effort which is currently airing. Those advertisements — featuring soothing music, cancer survivors and scientists — focus on the added years of life new drugs have provided to patients and convey patients’ optimism for a plethora of treatments still in development.The ads are also expected to convey messages similar to those in Pfizer’s new campaign, which chronicles a drug’s journey from concept to medicine cabinet. The group wants to highlight that it takes dozens of years, the overcoming of multiple setbacks and complex clinical trials — in other words, lots of money — to develop a drug.PhRMA is also meeting with political and industry insiders who will shape policy on drug prices. In July, the PhRMA board met with Clinton health policy adviser Chris Jennings, Anthem CEO Joe Swedish, Republican health economist Gail Wilensky and Steve Pearson of ICER, a research organization that analyzes the cost-effectiveness of drugs.PhRMA last month also met with Republican leaders in Congress, including Speaker Paul Ryan and Majority Leader Kevin McCarthy. A GOP lobbyist described the meeting with Ryan, which took place at an industry dinner, as the start of a conversation.By SARAH KARLIN-SMITHSome warn the new initiative as the potential to backfire.“Their actions will be judged, more than their words,” said Clinton health care adviser Jennings. “If they advertise in ways that they are denying the existence of a problem, or attacking people who are raising legitimate concerns on behalf of consumers and purchasers and businesses, and don’t engaging substantially on addressing the challenge, then they won’t be well received.”Jennings said Ubl, the PhRMA CEO, is “trying to send us a signal he wants to engage” on solutions for drug costs. But Jennings is worried that PhRMA’s growth will make the lobby even more powerful.“They are formidable under any scenario. They are formidable now,” Jennings said. “The idea that they are going to bring in more resources, borders on petrifying.”The challenge for PhRMA will be whether it can convince detractors the industry is not simply building up a bigger war chest to crush any policy proposal seen as undercutting its own agenda.“They talk a good game. … But when push comes to shove, they are not willing to budge on their public positions or their policy positions so it’s hard to give them any credit whatsoever,” said Topher Spiro, the vice president of health policy at the left-leaning think tank, Center for American Progress.Spiro pointed to industry’s strong opposition to Medicare’s recent proposal to pay less for the most expensive physician-administered drugs.“I think that this is all going to come to a head at some point over the next year or so,” he said, “so we’ll have to see if the drug industry wants to be seen as cooperative or as digging itself in.”Jennifer Haberkorn contributed to this report.Read more: http://www.politico.com/story/2016/08/drug-lobby-gears-up-for-massive-pr-campaign-226646#ixzz4GV5wr93uFollow us: @politico on Twitter | Politico on FacebookFacebookTwitterCopy LinkEmail
Your daily outdoor news bulletin for October 3, the day O.J. Simpson was acquitted in 1995:Leaf Peeping Party PooperOf all the things that don’t work during the current government shutdown, our National Parks are getting a lot of press for being closed. There is the political grandstanding and posturing at the World War II Memorial in D.C., the lost hikers in Crater of the Moon park in Idaho that may or may not be rescued by federal employees, there is the angry rafters at Grand Canyon National Park who have waited years – decades even – for their permits only to be stymied a the put-in, there’s the Panda Cam. It’s a mess for sure, and the economic impact is huge: estimates peg the total daily economic loss at $76 million with D.C. ($5.8 million), North Carolina ($4.4 million), Tennessee ($3.4 million), and Virginia ($3.3 million) all coming in the top 10 states with the biggest loses. Even for people in the government, that’s a lot of money. Although the Blue Ridge Parkway will remain open – the actual road, not the amenities – Great Smoky Mountains National Park and Shenandoah National Park remain closed. This includes all trails, visitors centers, etc. The month of October is one of the busiest months for both these parks, with GSMNP drawing upwards of a million visitors, all of whom have one thing in mind: leaves. The changing colors of the epic expanses of forests is one of the main reasons these two parks are so popular during the fall season. Most national forest trails remain open, even if the facilities are closed. There are some people who will still be able to enjoy our national parks however, those with leases to drill and those that want to log the forests. And then there are the small acts of civil disobedience like the situation at the Pisgah Inn.BEARS! THEY’RE EVERYWHERE!Over the past couple of weeks, a spike in bear activity has North Carolinians on edge. They only have one party to blame, and no it’s not the government shutdown – although I’m sure it hasn’t helped authorities deal with the bears. No, they can blame that smallest of nuggets that always tend to stab you in the sweet meat on the bottom of your arch when you walk barefoot to the mailbox: the acorn. A poor acorn crop in the high country has resulted in more bear activity in valley communities like Asheville as the winter hibernation season comes on. Bears are looking for food, and when there is a shortage, the easiest place to find it is in the trashcans of their neighbors, the hungry humans. Although they are mainly on the hunt for acorns at lower elevations, which are plentiful, a bear sighting at Asheville High School put that school on lock down yesterday, and a bear cub was hit by a car on I-26. Experts say to expect the increase in bear activity at lower elevations to continue through the fall and into the winter.Fracking Tearing Up Pennsylvania ForestsThe process of extracting natural gas from the ground via hydraulic fracturing is a relatively new process, and remains unregulated by the EPA, and as such has unknown impacts on the environment and communities. Some of those impacts are known – West Virginians lighting their tap water on fire is the example that immediately comes to mind – but now some more in-depth, more insidious, impacts of fracking are coming to light. A survey has revealed sweeping damage at fracking sites in Pennsylvania, one of the most controversial states when it comes to fracking because there is much public outcry but the states sits on the Marcellus Shale, which many consider the motherlode of deposits. Aerial photos and analysis reveal that fracking is causing sweeping damage and forests fragmented by new well pads, roads, and pipelines. Even a small amount of well sites have a major impact on the surrounding forests, and a deeper look at how ecosystems work reveals why. The theory of island biogeography says that an area’s diversity plummets when habitat is broken up into smaller pieces, as is happening where these drilling sites are, because some animals can only survive in the depths of the forest, not around it’s edges.Read the full story at grist.org.
Anthony Joshua has finally admitted he had to ‘grieve’ after losing his heavyweight titles to Andy Ruiz in a shock loss in June.He handed over his WBO, IBF and WBA and IBO belts to the Mexican after defeat in the seventh round having been knocked down four times.The pair will fight once again in Saudi Arabia on December 7, and Joshua insisted the first loss of his career was just a ‘blip’. According to UK’s Daily Mail, Joshua said: ‘I think I had to grieve and ask myself all the questions you would expect. ‘People say ‘you lost’, I call it a blip.‘I can’t wait to get in there and fight him. Every time I have fought a champion I have risen to the occasion.’Joshua also revealed he could change his approach in order to be more proactive at the start of fights.‘I need to start taking this approach to my fights where I’m a bit more lively.‘I know I’m capable of it. There is too much at stake.‘If I go in there where I’m switched on, a time like the Ruiz fight where I am so relaxed, that might be the difference.’Share this:FacebookRedditTwitterPrintPinterestEmailWhatsAppSkypeLinkedInTumblrPocketTelegram Anthony Joshua